Floatz logo

Clobazam

Anxiety Disorder

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Small moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Anxiety Disorder cohort.

Asset / SponsorPhaseRating
Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 4BBB
Risperidone
Tianjin Medical University General Hospital
Phase 4BBB
Olanzapine
Tianjin Medical University General Hospital
Phase 4BBB
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Theresa Jacob, PhD, MPH
Phase 4BBB
Fluoxetine
Hannover Medical School
Phase 4BBB

View all 50 →

Same molecule, other indications

Clobazam is also rated in:

epilepsyDormant
BB
Indicative · Phase 4
65 / 100
View asset →
generalized epilepsyDormant
BB
Indicative · Phase 3
65 / 100
View asset →
Lennox-Gastaut syndromeDormant
B
Indicative · Phase 3
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →